What drove today's EVE.SW stock move on the SIX?

Intraday buying increased volume to **13,500** shares, pushing price to **CHF 0.97**. The move follows a recent earnings update and improved technical momentum (RSI **60.99**, ADX **70.95**). Market interest and low float amplified the intraday gain.

What are the key valuation metrics for EVE.SW stock?

EvoNext shows **EPS -0.12**, **PE -8.08**, **PB 1.12**, cash per share **CHF 0.87**, and market cap **CHF 6,995,205.00**. These figures point to a cash-rich but currently loss-making small biotech.

What targets does Meyka AI give for EVE.SW stock?

Meyka AI's model lists a near-term target **CHF 1.20** and a yearly projection **CHF 1.84**. Against **CHF 0.968**, the yearly model implies **~90.28%** upside. Forecasts are projections and not guarantees.

Is EVE.SW stock a buy after the intraday rally?

The intraday rally shows momentum, but Meyka AI’s grade is **B (HOLD)** due to negative earnings and small market cap risks. Traders may buy short term with strict stops; longer-term buys need clearer earnings improvement.

CH Stocks

EVE.SW EvoNext Holdings S.A. (SIX) +5.22% intraday 24 Feb 2026: momentum may signal upside

ByDanny Kontos February 24, 2026

EVE.SW stock jumped 5.22% intraday on 24 Feb 2026, trading at CHF 0.97 after an early session bid pushed volume to 13,500 shares. The move follows a recent earnings update and improved momentum indicators that put the stock above its 50-day average of CHF 0.82. Traders on the SIX exchange are watching liquidity (average volume 7,362) and valuation metrics—EvoNext Holdings S.A. shows EPS -0.12 and PE -8.08—as short-term buying meets still-fragile fundamentals in the Swiss biotech healthcare segment.